Literature DB >> 20951086

Murine models of acute and chronic lung infection with cystic fibrosis pathogens.

Alessandra Bragonzi1.   

Abstract

Animal models of acute and chronic infection, along with mice genetically modified for the Cftr gene, are a key asset in cystic fibrosis (CF) research. Despite some limitations, these models provide valuable resources to mimic the initial and progressive bronchopulmonary infection typical of CF patients. The following review summarizes the strengths and weaknesses of different types of animal models with a major emphasis placed on the significant species differences between mice and humans. Murine models of acute and chronic lung infection with Pseudomonas aeruginosa, Burkholderia cenocepacia, Staphylococcus aureus, and Haemophilus influenzae have been used to study the molecular mechanisms underlying the pathogen virulence and host defense. In addition, they have provided insights in the potential of vaccination to restrict infectious exacerbations, the activity of antibiotics, and the effectiveness of anti-inflammatory therapy in reducing lung damage. Indeed, animal models of infection should allow the validation of future therapeutic interventions for lung infections in patients with CF.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20951086     DOI: 10.1016/j.ijmm.2010.08.012

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  56 in total

1.  Long term chronic Pseudomonas aeruginosa airway infection in mice.

Authors:  Marcella Facchini; Ida De Fino; Camilla Riva; Alessandra Bragonzi
Journal:  J Vis Exp       Date:  2014-03-17       Impact factor: 1.355

2.  Abnormal expression of Muc5b in Cftr-null mice and in mammary tumors of MMTV-ras mice.

Authors:  Hélène Valque; Valérie Gouyer; Marie-Odile Husson; Frédéric Gottrand; Jean-Luc Desseyn
Journal:  Histochem Cell Biol       Date:  2011-10-18       Impact factor: 4.304

Review 3.  Genetic modifications of pigs for medicine and agriculture.

Authors:  Jeffrey J Whyte; Randall S Prather
Journal:  Mol Reprod Dev       Date:  2011-06-10       Impact factor: 2.609

Review 4.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

Review 5.  Pseudomonas biofilm matrix composition and niche biology.

Authors:  Ethan E Mann; Daniel J Wozniak
Journal:  FEMS Microbiol Rev       Date:  2012-01-23       Impact factor: 16.408

6.  Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids.

Authors:  Anna Caretti; Michele Vasso; Fabiola Tecla Bonezzi; Andrea Gallina; Marco Trinchera; Alice Rossi; Raffaella Adami; Josefina Casas; Monica Falleni; Delfina Tosi; Alessandra Bragonzi; Riccardo Ghidoni; Cecilia Gelfi; Paola Signorelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-24       Impact factor: 3.000

Review 7.  The Collaborative Cross mouse model for dissecting genetic susceptibility to infectious diseases.

Authors:  Hanifa Abu Toamih Atamni; Aysar Nashef; Fuad A Iraqi
Journal:  Mamm Genome       Date:  2018-08-24       Impact factor: 2.957

Review 8.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

9.  Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.

Authors:  Giada Farinelli; Raisa Jofra Hernandez; Alice Rossi; Serena Ranucci; Francesca Sanvito; Maddalena Migliavacca; Chiara Brombin; Aleksandar Pramov; Clelia Di Serio; Chiara Bovolenta; Bernhard Gentner; Alessandra Bragonzi; Alessandro Aiuti
Journal:  Mol Ther       Date:  2016-07-26       Impact factor: 11.454

Review 10.  Genetically modified pigs to model human diseases.

Authors:  Tatiana Flisikowska; Alexander Kind; Angelika Schnieke
Journal:  J Appl Genet       Date:  2014-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.